Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours by Linton, K M et al.
Acquisition of biologically relevant gene expression data by
Affymetrix microarray analysis of archival formalin-fixed
paraffin-embedded tumours
KM Linton*,1,2, Y Hey
3, E Saunders
3, M Jeziorska
2, J Denton
2, CL Wilson
3,4, R Swindell
1, S Dibben
3, CJ Miller
3,
SD Pepper
3, JA Radford
1,5 and AJ Freemont
2
1Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX,
UK;
2School of Clinical and Laboratory Sciences, The University of Manchester, Oxford Road, Manchester, M13 9PT, UK;
3Cancer Research UK Paterson
Institute for Cancer Research, The University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, UK;
4Almac Diagnostics, Seagoe
Industrial Estate, Craigavon, BT63 5QD, Northern Ireland;
5School of Cancer and Imaging Sciences, The University of Manchester, Oxford Road,
Manchester, M13 9PT, UK
Robust protocols for microarray gene expression profiling of archival formalin-fixed paraffin-embedded tissue (FFPET) are needed to
facilitate research when availability of fresh-frozen tissue is limited. Recent reports attest to the feasibility of this approach, but the
clinical value of these data is poorly understood. We employed state-of-the-art RNA extraction and Affymetrix microarray
technology to examine 34 archival FFPET primary extremity soft tissue sarcomas. Nineteen arrays met stringent QC criteria and were
used to model prognostic signatures for metastatic recurrence. Arrays from two paired frozen and FFPET samples were compared:
although FFPET sensitivity was low (B50%), high specificity (95%) and positive predictive value (92%) suggest that transcript
detection is reliable. Good agreement between arrays and real time (RT)–PCR was confirmed, especially for abundant transcripts,
and RT–PCR validated the regulation pattern for 19 of 24 candidate genes (overall R
2¼0.4662). RT–PCR and
immunohistochemistry on independent cases validated prognostic significance for several genes including RECQL4, FRRS1, CFH
and MET – whose combined expression carried greater prognostic value than tumour grade – and cmet and TRKB proteins. These
molecules warrant further evaluation in larger series. Reliable clinically relevant data can be obtained from archival FFPET, but
protocol amendments are needed to improve the sensitivity and broad application of this approach.
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Whole-genome microarray gene expression profiling has rapidly
become the gold standard platform for retrospective prognostic
and predictive gene discovery in human cancers, but currently
depends on fresh-frozen tissue (FT) as a source of high quality
RNA. The majority of archival tumour specimens exist as routinely
prepared formalin-fixed and paraffin-embedded tissue (FFPET),
which is generally regarded as being unsuitable for microarray
applications due to the presence of degraded and chemically
modified RNA. Whereas RT–PCR interrogation of archival FFPET
has proven to be a reliable tool and is widely used (Cronin et al,
2004), this approach is unsuitable for large scale discovery-based
investigation owing to the limited number of genes that can be
assayed in one experiment. RNA from freshly prepared FFPET may
be minimally degraded (von Ahlfen et al, 2007) and their transcript
profiles correlate very well with those from paired unfixed FT (Lee
et al, 2005a; Scicchitano et al, 2006; Frank et al, 2007), but these
samples lack the requisite clinical follow-up data for correlation
with expression data.
RNA degradation per se does not preclude microarray analysis
with Affymetrix platforms (Schoor et al, 2003; Lee et al, 2005b),
which by design are ideally suited to interrogate RNA fragments.
Chemical modifications on the other hand not only hinder RNA
extraction but also impede reverse transcription and amplification
reactions (Godfrey et al, 2000; Lee et al, 2005b). The main concern
with using routinely prepared/archival FFPET for microarray
profiling is that ‘block effects’, such as pre-fixation time, size of
specimen being fixed, formalin/tissue processing conditions and
length of time in storage, will have variable effects on RNA
degradation and modification rates and consequently adversely
affect the reliability and clinical interpretation of microarray data.
The impact of ‘block effects’ on RT–PCR and microarray
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sperformance is only just coming to light (Penland et al, 2007; von
Ahlfen et al, 2007), but may not be as problematic as feared
especially considering that RT–PCR (the gold standard assay for
FFPET interrogation) has demonstrated reliable performance
despite the presence of these factors. This may also be true for
microarray applications. In a study of 157 archival FFPET samples
aged 2–8 years, correct classification of tumour type and subtype
using an unsupervised approach suggests that biological data are
more powerful than ‘block effects’ (Penland et al, 2007).
Furthermore, several groups have compared FT and FFPET arrays
in paired and unpaired samples and have shown that archival
FFPET specimens can retain valuable and reliable transcript data.
For example, using Illumina manufactured cancer-specific oligo-
nucleotide bead microarrays and DASL amplification of hybridised
templates, Bibikova et al found similar transcript profiles in
routinely processed archival FFPET and paired FT specimens,
although fewer genes were detected in FFPET (Bibikova et al,
2004), while Haque et al used FFPET arrays to independently
validate gene expression profiles obtained from FT samples of
paediatric glioblastoma (Haque et al, 2007). More recently,
Bibikova et al were able to show that archival FFPET expression
signatures correlate with Gleason score in relapsed prostate cancer
(Bibikova et al, 2007), attesting to the clinical and prognostic value
of FFPET transcripts.
It is apparent that highly concordant qualitative data can be
obtained for genes called ‘present’ in paired archival FFPET and FT
22K oligonucleotide arrays, especially for better quality FFPET (as
evidenced by the presence of ribosomal peaks) (Coudry et al,
2007), but the reproducibility of quantitative data (i.e. relative gene
expression fold changes) and degree of concordance when
nonexpressed (‘absent’) genes are taken into account is poorly
understood.
These studies raise an important question: can FFPET profiles
be used de novo to generate valid quantitative prognostic data? The
primary objectives of our study were first, to test whether
microarray profiling of archival FFPET can provide similar
quantitative data to those obtainable from RT–PCR and second,
to determine whether these data have clinical/prognostic relevance.
Confirmation of these aims would support the notion of using
archival FFPET profiling for biomarker discovery in tumours
where FT is in short supply. We chose to study extremity soft
tissue sarcoma (STS) as an example of a rare tumour where the
vast majority of tissues exist only as FFPET. A secondary aim was
to identify promising prognostic biomarkers in this disease entity.
MATERIALS AND METHODS
Study population
Cases of completely resected, localised, extremity STS (leiomyo-
sarcoma, liposarcoma and synovial sarcoma) were retrospectively
identified from Christie Hospital and Manchester University
Medical School Records. Pathological and clinical follow-up data
were collected for all patients. Two prospectively identified cases
(a leiomyosarcoma and spindle sarcoma not otherwise specified)
were included for assessment of paired FFPET and FT. Twelve
benign tumours (seven lipomas and five leiomyomas) were
collected from University archives for comparison of gene
expression with their malignant counterparts.
Preparation of tissue samples
Tissues were used in accordance with multi-centre research ethics
committee guidance and with informed patient consent. FFPET
samples were retrieved from local pathology departments where
they had been routinely processed and stored for 1–8 years (mean
6 years). Ten-micron thick sections were cut from representative
tissue blocks. After discarding the top few sections (to eliminate
oxidised/contaminated tissue), viable tumour and adjacent stromal
tissue areas were carefully macrodissected from tissue sections
using a scalpel and dissecting microscope. Care was taken to avoid
contamination by exogenous RNases and sample cross contamina-
tion by changing gloves frequently, decontaminating all surfaces
and equipment with RNase eliminating solutions and cleaning with
xylene between samples to eliminate wax carryover.
FT samples were collected in the operating theatre, divided
into 1.0cm
2 pieces and immediately placed in TRIzol reagent
(Invitrogen, CA, USA) prior to freezing at  801C.
RNA extraction
Total RNA was isolated from FFPET using the Optimum FFPE
extraction protocol (Ambion Diagnostics, TX, USA), with minor
modifications, including incubation with a further 300 units of
proteinase K at 501C for 2–4h for samples with residual
undigested tissue as this gave significantly higher purity and
yields of total RNA (data not shown). RNA was extracted from
thawed, homogenised FT using the TRIzol method, according to
manufacturer’s instructions. All RNA samples were DNase-treated
(Optimum Kit) and purified (RNeasy Micro Kit, Qiagen, Hilden,
Germany). Total RNA yield and purity were estimated by
ultraviolet spectroscopy (Nanodrop ND-1000 Spectrophotometer,
Nanodrop Technologies, DE, USA) and quality was assessed on an
Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA).
Affymetrix expression microarrays
Thirty-four FFPET samples were selected for microarray experi-
ments based on total RNA yield 42mg and 260 of 230 ultraviolet
absorbance X1.8. Two micrograms of total RNA were used to
prepare biotinylated target RNA using the Affymetrix One Cycle
Target Preparation Protocol driven by T7-linked oligo(dT)
primers. Manufacturer’s recommendations were followed, apart
from complementary RNA fragmentation, which was shortened to
15min. Samples were hybridised overnight to Affymetrix HG U133
Plus 2.0 arrays, scanned and processed using GeneChip Operating
Software. Analyses were performed using BioConductor (Gentleman
et al, 2004). RMA and MAS5 data were produced using the
implementations found in the ‘affy’ (Gautier et al, 2004) and
‘simpleaffy’ (Wilson and Miller, 2005) BioConductor packages.
MAS5 expression calls were generated using the simpleaffy
implementation of (Hubbell et al, 2002) and detection calls with
the simpleaffy implementation of (Liu et al, 2002). Unless
otherwise stated, a1 and a2 values were 0.05 and 0.065 respectively,
the default values for these arrays. All MAS5 data were scaled to a
target intensity of 100.
Selection of microarray training samples based on
Affymetrix QC parameters
As expected, all FFPET samples contained extensively degraded
RNA with a mean RIN of 2.2. (1.2–3.6). There was no statistical
difference in the RIN values for training and nontraining sets
(P¼0.51, Mann–Whitney U test); training set median RIN 2.3 (2–
3.6, n¼18), nontraining median RIN 2.2 (1.2–2.4, n¼15). RIN
values for FT samples were 3.1 and 5.5. FFPET purity was
satisfactory (mean 260/280 of 2.03 and mean 260/230 of 1.70)
(Supplementary Table S1). Almost half (15 of 34) of FFPET arrays
failed to meet one or more recommended Affymetrix quality
control criteria for inclusion in the analysis. The remaining 19 of
34 FFPET arrays – which met the criteria, including scale factors
within threefold of each other and present calls ranging from 20–
30% – were used as a prognostic training set (Figure 1). These
arrays still exhibited significantly lower percent present (PP) calls
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sthan is expected from high quality samples and high 30 of 50 ratios,
in keeping with the poor quality of FFPET RNA samples.
Microarray data analysis
Several rounds of supervised data analysis were used to identify
probe sets upregulated or downregulated in metastatic and
nonmetastatic outcome cases. The detection call (Liu et al, 2002)
was used to identify probe sets with a signal intensity not
substantially above background. In the initial round of analysis
(Gene list 1), probe sets were eliminated from the analysis unless
they were consistently flagged as present (i.e. reliable) in all
samples, since it is not possible to distinguish between those
flagged absent (i.e. close to background level) due to low gene
expression, and those flagged absent due to poor RNA quality.
Data were filtered on the basis of z-score and fold change to
generate the first gene list. A 19-gene signature obtained by K-
Nearest Neighbour separation (k¼3) and leave-one-out cross
validation (LOOCV) demonstrated 100% accuracy for classifica-
tion, however, fold changes were considered to be too small for
reliable RT–PCR validation. It was therefore decided to include all
probe sets (i.e. those flagged present and absent) in subsequent
rounds of analysis.
A 500-gene signature was generated using the survival package
in R to generate log-odds scores for every probe set on the array
(Gene list 2). Functional annotation identified many genes in this
list with described roles in cancer biology, suggesting that
differential expression was indeed a reflection of underlying
biology and not merely borne of statistical chance. The 500-gene
list was sorted in order of P-value and validated by LOOCV.
A series of increasingly less stringent filter cutoffs was used to
generate several probe set lists of different lengths. These were
used as input to the globaltest package in BioConductor (Goeman
et al, 2004) to investigate the performance of probe sets when
grouped together as a set (rather than treated individually). In this
way, a signature comprising the top 50 probe sets was identified
(Gene list 3). Changing the filtering parameters to include or
exclude probe sets from this list resulted in reduced performance,
that is, the 50-gene signature represented the smallest number of
genes with collective prognostic power. We used the survival
package in R (with samples grouped by median expression) to
generate Kaplan–Meier (KM) plots for the 19 FFPET arrays to test
the relationship between microarray gene expression and survival.
This approach is similar to those of (Chi et al, 2006; Winter et al,
2007). Receiver operating characteristic curves (ROC) for the 500-
gene probe sets illustrate the sensitivity and specificity of detecting
metastases within 3 years of diagnosis by gene expression, showing
good performance with AUC values of 0.85 and 0.92 for up- and
downregulated profiles respectively. These data are illustrated in
Figure 2 and full gene lists are given in Supplementary
Information.
Candidate gene selection for individual performance
validation by RT–PCR
As our primary objective was to test whether quantitative
microarray data was reproducible by RT–PCR for archival FFPET,
we selected genes from the 500- and 50-gene signatures for
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Figure 1 (A) Affymetrix quality control parameters for all FFPET arrays: displayed in the first column, present calls (top) are highly variable (from 8.8 to
33.8%) while background (bottom) is fairly constant across the dataset. Scale factors should be within threefold of each other for arrays to be comparable;
range of scale factors (horizontal lines) is 3.64–21.61, with many falling outside the three-fold dotted lines. GAPDH and ß-actin 3050 ratios (circles and dots)
are extremely high and effectively indicate that the 50 probe set is absent – even the 30 mid ratios are too high and fall outside Affymetrix recommendations.
(B) Percent present and scale factors for selected training FFPET arrays: restricting analysis to those samples with a percent present call greater than 20 but
less than 30 (middle ‘training series’ group) gave 19 samples (nine nonrecurrent, 10 metastatic recurrence) with 3343 probe sets called present on all arrays
(3292 after eliminating AFFX probe sets). Scale factors are generally within threefold for training samples.
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sindividual performance validation by RT–PCR. Twenty-four
candidate genes were chosen based on differential fold change
between metastatic and nonmetastatic outcome cases, P-value,
clinical relevance (Table 1) and the ability to design efficient
primer pairs for RT–PCR validation. The number correctly
classified by LOOCV and associated P-value was also used for
selecting genes from the 50-gene list. A heatmap depicting the 24
genes is shown in Figure 3.
Real-time quantitative PCR
Assays were designed using ProbeFinder software (Available
at: https://www.roche-applied-science. com/sis/rtpcr/upl/adc.jsp).
Where possible, identical Plus 2.0 array targets were interrogated,
otherwise the Affymetrix consensus sequence was used. Primers
were synthesised by Invitrogen (Paisley, UK) and labelled
probes were obtained from the Human Universal Probe Library
(Roche, Switzerland). Primer and probe details are given in
Supplementary Table S2. CDNA was synthesised using TaqMan
Reverse transcription reagents (Reverse-It Kit, ABI, CA, USA)
primed with random hexamers, in reaction volumes of 50ml for
1mg total RNA.
Experiments were performed in triplicate on an ABI 7900 Real-
Time Sequence Detection System in 384-well format. Assays were
tested for efficiency using Human Reference Total RNA (BD
Biosciences, CA, USA) and a 10-fold dilution series. Only assays
with a slope between  3.00 and  3.60 were carried through.
Manufacturer’s standard PCR conditions were used and results
were analysed using SDS 2.1 (ABI). Mean gene expression Ct values
were normalised to the mean expression of two reference genes
(KIAA0446 [32091_at] and INTS5 [53968_at] (Supplementary
Figure S1). Reference genes were chosen from microarray data
for their consistent performance compared with 15 commonly
used reference genes and similar stability across RT–PCR assays
was confirmed by Genorm analysis (data not shown) (Vandesompele
et al, 2002).
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Figure 2 (A) Heat map of hierarchical clustering for 500 differentially expressed genes: horizontal rows represent individual genes and vertical rows
represent individual patients, grouped by metastatic/no metastatic recurrence. Suffix ‘A’ denotes surviving patients, ‘D’ denotes those who have died of
disease, ‘DO’ identifies one patient who did not have recurrent disease at the time of death from nonsarcoma causes. Each cell in the matrix represents the
expression level of a single transcript in a single sample, with red and green indicating transcript level above and below the median for that gene across all
samples, respectively. It is noteworthy that the expression pattern for the patient who died of nonsarcoma causes shares similarities with those for patients
alive without metastases. Highest pattern homology is seen for patients who have died of metastatic disease. (B) Log-rank KM plots for up- and
downregulated transcripts are shown for samples grouped above/below median gene expression. (C) ROC curves and AUC values illustrate sensitivity and
specificity of detecting metastatic recurrence within 3 years of diagnosis.
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sCandidate protein selection for performance validation by
immunohistochemistry on tissue microarrays
Validation at protein expression level is necessary to fully explore
the clinical utility of promising biomarkers, especially as the extent
to which mRNA changes are accompanied by similar changes at
protein level is highly variable. We were particularly interested in
testing known ‘cancer’ genes found to be differentially regulated on
FFPET arrays. Dysregulation within the tyrosine ‘kinome’, which
includes targets such as c-kit, VEGF, EGFR, is proving to be
Table 1 Candidate prognostic classifier genes for soft tissue sarcoma ranked by log2 discriminatory fold change
Gene symbol Affymetrix probe set id Accession Unigene Log2
a Gene list source P-value* Cancer function
PPP1R1A 205478_at NM_006741 Hs.505662 3.28 List 2 0.001 Yes
NTRK2 221796_at AA707199 Hs.494312 3.26 List 2 0.004 Yes
FRRS1 1570207_at BC029438 Hs.454779 2.78 List 2 0.002 Not known
ADRB1 229309_at AI625747 Hs.99913 2.76 List 2 0.001 Yes
CFH 213800_at X04697 Hs.2637  2.70 List 2 0.003 Yes
ZNF165 206683_at NM_003447 Hs.55481  2.58 List 2 0.006 Yes
CALCR 207887_s_at AB022177 Hs.489127 2.50 List 2 0.002 Yes
CMAH 1554862_at BC022302 Hs.484918  2.49 List 2 0.006 Not known
MET 203510_at BG170541 Hs.132966  2.47 List 2 0.003 Yes
HMGA1 206074_s_at NM_002131 Hs.518805  2.43 List 2 0.005 Yes
PPP1R14A 227006_at AA156998 Hs.348037 2.34 List 2 0.009 Yes
TYRP1 205694_at NM_000550 Hs.270279 2.33 List 2 0.001 Yes
TPM4 235922_at AW629304 Hs.466088 2.33 List 2 0.009 Not known
ADAMTS9 1556413_a_at AF086538 Hs.549184 2.29 List 2 0.010 Yes
GHR 205498_at NM_000163 Hs.125180 2.28 List 2 0.006 Yes
NA 1562932_at BC015135 NA 2.05 List 2,3 0.001 Not known
NA 233162_at AK024336 NA 1.91 List 2,3 0.004 Not known
SLC2A3 202499_s_at NM_006931 Hs.419240 1.88 List 2,3 0.002 Yes
SOX4 213668_s_at AI989477 Hs.357901  1.87 List 3
b Yes
CACNG1 206612_at NM_000727 Hs.147989 1.59 List 2,3 0.004 Not known
RECQL4 213520_at NM_004260 Hs.31442  1.54 List 2,3 0.004 Yes
FLJ10292 218894_s_at NM_018048 Hs.104650  1.47 List 2,3 0.003 Not known
MNAB 231716_at AF255304 Hs.533499  1.45 List 3
b Not known
MOXD1 209708_at AY007239 Hs.6909  1.45 List 2,3 0.003 Not known
b
aLog2 fold changes differ from those obtained from scaled MAS5 processed data because unscaled data were used (see text). *P-values obtained from List 2.
bIndividual P-value
not applicable as gene derived from List 3 where expression and significance of groups of genes were considered.
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Figure 3 Heat map of hierarchical clustering for 24 selected differentially expressed genes: horizontal rows represent individual genes and vertical rows
represent individual patients. Red and blue indicate transcript level above and below the median for that gene across all samples, respectively. Distinct
clusters of differentially expressed genes can be seen for patients grouped by metastatic/no metastatic recurrence.
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scritically important for tumour development and progression
(Bardelli et al, 2003). Two receptor tyrosine kinases – MET (which
encodes cmet) and NTRK2 (which encodes TRKB) – were found to
be highly differentially regulated in our array dataset and, as
commercially prepared antibodies were available, they were
chosen for protein validation using immunohistochemistry on
specially constructed tissue microarrays (TMA).
TMA construction
Tissue microarrays of extremity STS were constructed in-house
using an ATA-100 tissue arrayer (Chemicon International, CA,
USA) according to manufacturer’s instructions. Each sample was
represented by up to four 1.5mm cores of viable tumour tissue, to
allow inclusion of heterogeneous tumour areas and to minimise
data loss occurring as a result of core loss or damage during
experimentation. TMA sections of 5mm-thickness were cut and
processed for immunohistochemistry experiments according to
standard tissue preparation protocols.
Immunohistochemistry
Polyclonal antibodies were purchased for TRKB (Promega,
catalogue no. G1561, WI, USA) and cmet (Zymed, catalogue no.
71–8000, CA, USA). The avidin–biotin complex approach was
optimised for each antibody. Briefly, deparaffinised and dehy-
drated sections were microwaved in citrate buffer, pH 6.0 for
antigen retrieval. Nonspecific staining was blocked using CAS
block (Zymed Laboratories, CA, USA). Following 41C overnight
incubation with primary antibody, tissues were treated with 2%
hydrogen peroxide and then incubated with secondary antibody
followed by streptavidin HRP, both for 45min. The reaction was
developed with SG chromogen (Vector Laboratories, CA, USA) and
sections were counterstained with Mayer’s haematoxylin (BDH
Laboratory Supplies, Poole, UK).
Computerised image analysis of immunostaining
One digital image per immunostained tissue core was acquired
using a Leica RMDB Research Microscope coupled with a DeltaPix
camera, and analysed using Quantimet 550 software and an in-
house macro written in QUIPS. This enabled automatic computer
detection and measurement of immunopositive features (Figure 4).
Images were converted to grey scale and each pixel was allocated a
value corresponding to its ‘grey shade’. The range of values
representing positive staining was previously determined for each
antibody by examining staining in positive and negative controls.
The sum of all grey values (‘sum grey’) was used to compute
quantitative protein expression. For qualitative purposes, samples
were considered to have high protein expression if sum grey
exceeded the median expression value.
Statistical analyses
Statistical analyses were carried out in Excel and with SPSS
(Statistical Package for Social Sciences) version 10.1. Relative gene
expression was computed using the 2^delta–delta Ct method
where delta–delta Ct is the difference between mean (of triplicate
reactions) normalised expression in metastatic recurrence and
nonrecurrent cases. Relative protein expression was computed as
the ratio between mean sum grey data in metastatic recurrence and
nonrecurrent cases. The Mann–Whitney test was used to compare
protein expression in benign and malignant tumours and
Kruskal–Wallis to compare expression in nonrecurrent, locally
recurrent and metastatic recurrent STS. KM analyses were
performed using the log-rank test and hazard ratios for
metastasis-free survival were generated. AUC values for promising
genes were computed. We were also interested in comparing gene
expression performance with tumour grade. To do this, we
developed a simple scoring system based on gene expression of
four promising genes (described in the results section) and used
the log-rank test to compare gene score and grade for prediction of
metastases within 3 years of diagnosis (see Results).
RESULTS
Patient and sample characteristics
Patient and tumour characteristics for 19 FFPET array training
cases are summarised in Supplementary Table S3. Median follow-
up for surviving patients (n¼12) was 52.5 months (19–81
months). Ten patients developed distant metastases, with a median
time to metastasis of 21 months (2–46 months). At the time of
analysis, there were four surviving patients with metastases. One
elderly patient without metastases died of nonsarcoma causes.
Patient and tumour characteristics for remaining cases are
summarised in Supplementary Table S4. RT–PCR cases (n¼69)
included 15 cases profiled on microarrays but excluded from
microarray analysis and 54 independent cases. Immunohistochemistry
cases (n¼85) included 49 of 50 cases also examined by RT–PCR and
32 of 34 cases also profiled by gene microarrays. Median follow-up for
surviving patients (n¼50) was 68 months (19–202 months).
Comparison of data from paired FFPET and FT RNA
samples
We related the performance of FFPET arrays to paired FT arrays to
test their sensitivity and specificity (sample pairs KL35/KL39 and
A B
20 m
Figure 4 Illustration of cmet immunostaining and computerised image analysis detection of immunostained features in a case of synovial sarcoma. (A)
Immunopositive areas are dark grey (SG chromogen) and background is light grey, (B) computer detected features are marked with blue overlay, which
confirms excellent detection of immunopositive areas shown in A.
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sKL36/KL40). The RIN values for FT samples were unexpectedly
low (mean 4.3) but, as mentioned earlier, RNA degradation is not
believed to significantly affect the percentage of genes called
present on Affymetrix arrays (Schoor et al, 2003; Lee et al, 2005b).
Despite low RIN values, PP rates from the FT arrays were well
within the normal range of values seen across all Plus 2.0 arrays
run on frozen samples in our laboratory (data not shown). For
example, KL39 had RIN 5.5 and PP 48.9% and KL40 had RIN 3.1
and PP 53.5%. This suggests that these FTs were valid reference
samples. As expected from previous reports, FFPET array
sensitivity was approximately 50% of paired FT (PP 27 vs 49%
for KL35/39 and 28 vs 53% for KL36/40). Only 3–4% of present
probe sets were found exclusively in FFPET. This corresponds to
high FFPET array specificity (95–96%) and positive predictive
value (92–94%), which attest to the reliability of present calls from
FFPET arrays (Figure 5). The extent to which FFPET data
resembles FT data increased with abundance of expression on
arrays (e.g. R
2¼0.06 for signal intensities between 5 and 6,
compared with R
2¼0.49 for signals over 10). Similarly by RT–
PCR, genes detected in FT after B30 cycles were poorly detected in
paired FFPET, while there was generally good agreement for more
abundant genes (Supplementary Figure S2). Unfortunately,
although these would have been useful, technical replicates were
not run for microarrays.
Comparison of data from array and RT–PCR platforms
Real time–PCR is regarded as the ‘gold standard’ assay for
validating microarray data (Wang et al, 2006), and was therefore
used to determine whether microarrays can reproduce the
technical ‘truth’ for gene expression. There was good agreement
for genes with abundant and consistent expression across the
sample series (from which reference genes were selected), as
evidenced by Genorm analyses (Supplementary Figure S1). Array
data were also generally reproducible by RT–PCR for differentially
expressed candidate genes of interest, with similar fold change
patterns, although reproducibility was lower when probing
for nonidentical sequences (overall R
2¼0.4662) (Figure 6).
Reproducibility was not affected when different RNA extracts
(from the same case) were used for RT–PCR and arrays (data not
shown).
Prognostic value of individual candidate genes and
proteins
The number of FFPET arrays used to generate a prognostic model
was small (n¼19) as almost half of FFPET arrays failed to meet the
quality control criteria for inclusion in the analysis. As expected,
prognostic value was not seen for all genes when tested across a
larger number of samples (Figure 7). Nevertheless, some genes
look promising at this early validation stage. Hazard ratios (HR)
for candidate genes and proteins significantly associated with
survival (Po0.05) or associated with a survival trend (Po0.1) are
given in Supplementary Figure S3. RECQL4 overexpression
increased the risk of metastasis±mortality (log-rank P¼0.001,
HR 5.2 Po0.000, while FRRS1 and CFH each reduced metastatic
risk (FRRS1 log-rank P¼0.005, HR 0.4 P¼0.017; CFH log-rank
P¼0.036, HR 0.44 P¼0.041. MET increased risk, although this did
not quite reach statistical significance (log-rank P¼0.06, HR 2.1
P¼0.069). At protein level, overexpression of cmet and TRKB each
increased metastasis risk (HR 2.3, P¼0.029 and HR 3.87,
P¼0.001, respectively) and, interestingly, their expression was
highly correlated (P¼0.002). Both TRKB and cmet proteins were
significantly overexpressed in malignant STS compared with
benign sarcomas (P¼0.001 and 0.015, respectively) and TRKB
overexpression was higher in cases with metastatic recurrence
compared with local or no recurrence (P¼0.05) (Supplementary
Figure S4).
Comparison of the prognostic power of tumour grade
and gene expression score
The major prognostic determinants for localised extremity STS are
histological subtype, grade and size, with grade alone being the
most powerful single prognostic predictor. Five-year survival rates
across all STS are 90, 70 and 45% for grades 1, 2 and 3, respectively
(Guillou et al, 1997). To compare the prognostic power of gene
expression with that of grade, we developed a scoring system based
on expression of four promising genes (RECQL4, FRRS1, CFH and
MET) and compared KM plots for metastasis-free survival (MFS)
according to grade and score.
For scoring purposes, gene expression was classified as
upregulated or downregulated according to expression above or
below the level with highest sensitivity and specificity for
metastasis detection within 3 years of follow-up, as determined
by ROC analysis (which for the most part approximated the
median value). In this dataset, upregulation of RECQL4/MET and
downregulation of CFH/FRRS1 favoured metastasis development.
Assuming that each gene has equal weighting, the reference was set
to represent the worst scenario for metastasis (i.e. upregulated
RECQL4 and MET and downregulated CFH and FRRS1). Scores
between 0 and 4 were allocated according to the correspondence
between observed and reference expression, with 4 representing
the exact match/worst scenario score. Scores were then related to
MFS using the log-rank test.
Interestingly, in this dataset, score was a more powerful
predictor of MFS compared with grade (P-values 0.0004 and
0.011 respectively) (Figure 8), although these were not independent
variables in a cox regression multivariate model. A score of 3 or 4
was associated with a much poorer MFS compared with scores of 2
or lower. Thus, even though the test value of gene expression is
poor according to individual AUC values (0.68 each for RECQL4
and FRRS1, 0.63 for CFH, 0.61 for MET, see Supplementary Figure
S5), in this dataset the combined performance of these genes was a
stronger predictor of MFS than grade, our current best prognostic
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Figure 5 Illustration of sensitivity, specificity, positive predictive values
(PPV) and negative predictive values (NPV) for FFPET data relative to
paired FT: Two paired FT and FFPET samples were used (cases 56 and 58).
Numbers refer to the number of probe sets flagged. TP¼true positive,
FP¼false positive, TN¼true negative, FN¼false negative. Sensitivity [TP/
(TPþFN)] is low, with only B50% of transcripts present in FT being
detected in FFPET, and corresponding NPV [TN/(TN/FN)] is only 34–
38%. Specificity [TN/(FPþTN)] is excellent (95–96%), suggesting that
detection calls in FFPET are reliable, with a PPV [(TP/(TPþFP)] of 92–
94%.
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spredictor. These genes are therefore worthy of future exploration
of their prognostic value in a larger cohort of extremity STS cases.
DISCUSSION
In this study, we set out to assess the feasibility of using archival
FFPET profiling for biomarker discovery in tumours where fresh-
frozen tissue is in short supply. Using state-of-the-art technology
at the time, including an RNA extraction kit from Ambion
(Optimum, Ambion, TX, USA) and Affymetrix Plus 2.0 HG
microarrays, we found that it is possible to identify promising
clinically relevant molecules from archival FFPET, although
further protocol amendments are needed to improve the sensitivity
of this approach.
The reliable application of archival FFPET profiling to answer
biologically relevant questions depends on the extent to which
quantitative gene expression relationships are faithfully preserved
in FFPET. As discussed earlier, several groups including ourselves
have confirmed that archival FFPET profiles mirror those in paired
FT samples (Bibikova et al, 2004; Haque et al, 2007), however it is
not yet clear how close the resemblance should be to achieve this
aim. In other words, does it matter that the sensitivity from FFPET
is only 50% if the data are reliable (as evidenced by high specificity
and positive predictive values of B95 and B92% respectively) and
provide reproducible prognostic information? It is nevertheless
desirable to improve the sensitivity of FFPET arrays. Low
sensitivity rates of around 50% relative to FT arrays have been
reported by others (Bibikova et al, 2004; Scicchitano et al, 2006)
and may be due to the presence of residual nonreversed chemical
modifications that reduce the efficiency or completely prevent in
vitro transcription to cRNA (Godfrey et al, 2000; Bibikova et al,
2004; Lee et al, 2005b). Our archival FFPET RNA samples were
similarly (and extensively) degraded, yet cRNA yields varied
widely (5–28mg). This suggests that there was significant variation
in inter-sample modification rates, presumably reflecting variation
in routine processing conditions. However, despite the presence of
variable ‘block effects’, relative quantification has been shown to
be unaffected as long as data are normalised to an internal
reference gene (Godfrey et al, 2000; Abrahamsen et al, 2003;
Almeida et al, 2004), as indeed was performed for our samples.
Furthermore, differential expression was validated by RT–PCR for
approximately one-third of transcripts (i.e. fold change expression
was similar by both assays). This is a promising result, especially
considering that RT–PCR and microarray data from the same
sample do not always correlate even when RNA quality is optimal.
For example, RT–PCR comparability is lower for genes with low
microarray signal intensities (weakly expressed or absent genes) –
as demonstrated in the present study – and with increasing
separation between the location of PCR primers and microarray
probes (Tsien et al, 2001; Etienne et al, 2004; O’Sullivan et al, 2005;
Wang et al, 2006). Thus RT–PCR confirmation of quantitative
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Figure 6 Comparison of paired microarray and RT–PCR assays for candidate genes: genes upregulated in cases with metastatic recurrence (and
reciprocally down regulated in nonrecurrent cases) are shown as positive fold changes (above the x-axis) and vice versa for negative fold changes. Error bars
are the standard error of the difference in the means. Similar upregulated/downregulated fold change patterns were seen for 19 of 24 candidate genes
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smicroarray data, even if only for a third of transcripts, lends
further support to the hypothesis that expression patterns are
preserved in archival FFPET, although further work is needed to
test this fully, including evaluation of technical replicates in a
larger dataset.
The use of oligo(dT) priming is a standard labelling approach,
but may have contributed to low gene detection rates in FFPET as
fragments discontinuous with the poly A tailed region cannot be
anchored to oligo(dT) primers. Preferential chemical modification
of adenine residues by formalin further compromises the
suitability of oligo(dT) for FFPET substrates (Masuda et al, 1999;
Paik et al, 2005). A direct comparison of random hexamer and
oligo(dT) priming has confirmed that random primers give higher
gene detection rates from FFPET (Xiang et al, 2003). The recently
NA[1562932_at]
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Figure 7 Real time–PCR validation: KM plots for 24 individual candidate genes in 60 samples according to gene expression above/below the median. A
statistically significant relationship with MFS was confirmed for five genes (RECQL4, FRRS1, CFH, ADAMTS9 and MNAB), while expression for MET, SOX4,
NA[1562932_at] and hypothetical protein FLJ10292 showed a nonsignificant trend for MFS in this dataset.
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slaunched Nugen and Nugen FFPE protocols utilising both
oligo(dT) and random priming are therefore especially promising
for FFPET substrates (Nugen Technologies, CA, USA) and are
likely to significantly improve the sensitivity of FFPET arrays.
The choice of microarray platform may also affect gene detection
rates. Affymetrix Plus 2.0 arrays used in the present study contain
multiple short (25-mer) probe sets located within B500bp of the 30
utr transcript regions. In our hands Plus 2.0 arrays are only
marginally inferior to X3P arrays (by 3–5%, unpublished data),
which contain probe sets within B300 bases of 30utr and are
marketed specifically for FFPET. The unique design features of
newer platforms such as the Affymetrix Exon arrays may be better
suited to archival FFPET interrogation and are worthy of further
investigation of their ability to improve gene detection.
Finally, gene detection is likely to improve with the use of newer
RNA extraction protocols that have been designed for superior
reversal of chemical modifications, albeit that a proportion of these
will remain irreversible (Masuda et al, 1999; Paik et al, 2005).
The second primary aim of this project was to establish whether
archival FFPET microarray-selected transcripts contain prognostic
relevance. Log-rank testing confirmed this to be the case for the
500- and 50-gene signatures and moreover functional annotation
confirmed known cancer roles for a large number of identified
genes. It would have been desirable to validate the full 50-gene
signature but, as we did not have the means to test the
performance of large numbers of genes by RT–PCR (including
the full 50-gene signature), we selected twenty-four candidate
genes for RT–PCR validation.
Successful RT–PCR validation was limited to some extent by the
small training series used for prognostic modelling especially
considering the heterogeneous histological nature of training
samples although, arguably, histological heterogeneity is less
important if the aim is to identify differentially regulated genes
that drive tumour behaviour across all subtypes. In our dataset,
survival analyses support prognostic roles for several differentially
regulated transcripts, including RECQL4, FRRS1, CFH, ADAMTS9,
MNAB, and to a lesser extent MET, SOX4, NA[1562932_at] and
hypothetical protein FLJ10292. Interestingly, the combined prog-
nostic effect of selected genes RECQL4, FRRS1, CFH and MET,a s
tested using a simple equal-weighted scoring system, was greater
than that of tumour grade, our current best prognostic test. This
finding alone strongly supports the hypothesis that archival FFPET
microarray-selected genes contain valuable prognostic relevance.
We were particularly interested in the downstream prognostic
effects of the protein tyrosine kinase family as the utility of
targeting their proteins for treatment of specific cancers is well
established and they are known to be highly expressed in a large
proportion of bone and soft tissue sarcomas (Baird et al, 2005). We
tested two protein tyrosine kinase receptors at protein level – cmet
and TRKB. Dysregulation of their signalling pathways are known
to be important mediators of the metastatic phenotype (Corso
et al, 2005; Desmet and Peeper, 2006). These proteins were
significantly upregulated in malignant compared to benign soft
tissue tumours (implicating a role in tumorigenesis) and moreover
significantly increased the risk of metastasis development in our
samples. Cmet has previously been detected in 52–87% of STS
(Fukuda et al, 1998; Kuhnen et al, 2003) and, an important proto-
oncogene itself, also enables sarcoma cells to become hyper-
responsive to HGF, a ubiquitously expressed effector of cell
proliferation, motility and invasiveness (Cortner et al, 1995).
Dysregulation of TRKB and its activating neurotrophin BDNF play
a role in tumorigenesis and metastasis in a wide range of
carcinomas (Han et al, 2007) but, to our knowledge, a role for
TRKB in sarcoma tumorigenesis and metastasis development has
not previously been described. Overexpression of TRKB also
mediates cmet activation via upregulation of HGF (Hecht et al,
2005) and cooperation between TRKB and cmet has been
implicated in the invasive capability of neuroblastoma cell lines.
Evidence of highly correlated expression in our study suggests that
similar cooperation between cmet and TRKB may be important for
metastatic progression in STS and could represent dual targeting
opportunities. Targeted therapies for cmet and TRKB are already
under evaluation in other tumours (Christensen et al, 2005;
Desmet and Peeper, 2006) and their potential value in STS
warrants evaluation in future clinical trials.
In conclusion, our preliminary findings suggest that microarray
gene detection from archival FFPET is reliable and capable of
identifying candidate prognostic genes in human tumours using
standard methodology, albeit with a gene detection rate of only
B50% compared with frozen tissues. Despite the limitations of the
approach we used, several candidate prognostic molecules for
extremity STS were identified in this dataset and are worthy of
prospective investigation of their prognostic value and/or potential
as therapeutic targets in extremity STS.
We anticipate that the sensitivity of this approach will improve
through the use of newer FFPET extraction protocols, combined
oligo(dT) and random hexamer priming and newly-developed
array platforms. The development of a highly reliable and robust
protocol for microarray analysis of archival FFPET appears to be
within reach and, with appropriate protocol improvements,
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Figure 8 KM plots for metastasis-free survival (MFS) according to grade and gene score (see text for explanation of gene score): gene score is a more
powerful prognostic predictor than grade in this dataset.
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spromises to become a valuable research tool, providing an entry to
the molecular investigation of tumours where supplies of FT are
limited or nonexistent.
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